“…In a double-blind, placebo-controlled trial involving patients with hepatitis C, treatment with the product was associated with a significant reduction in ALT levels, although no treated person cleared the virus. 43 NCCAM is currently supporting a study of a 10-herb combination, referred to as 3AR. The trial will assess safety and adverse events, as well as symptoms of fatigue, quality of life, liver function, and HCV-RNA levels in patients who do not qualify for standard therapy of hepatitis C. Thus, there is increasing interest in conducting rigorous testing of candidate CTM compounds (1) as alternatives to standard treatment, (2) to augment conventional treatments, or (3) to ameliorate the side effects of current therapies.…”